Olleyes.Inc

Olleyes Inc. is a medical device company developing advanced eye care testing technology, with its flagship product being the VisuALL visual field analyzer. This system incorporates artificial intelligence and virtual reality to provide more efficient and reliable ophthalmic evaluations. Designed for broad applicability, the device accommodates diverse patient populations across all age groups and physical conditions, allowing for testing in various positions.

The company was founded in 2018 by Alberto Gonzalez-Garcia and Freddy Morgenstern. Their foundational insight stemmed from a clear objective to transform and modernize the field of eye care, aiming to overcome limitations present in traditional diagnostic methods. This led to the development of their proprietary technologies, enhancing accessibility and precision in ophthalmic diagnostics.

Olleyes primarily serves eye care professionals seeking innovative solutions for patient diagnostics. The company's long-term vision centers on continually advancing eye care through technology, making diagnostic procedures more accurate, user-friendly, and accessible. It strives to set new benchmarks in ophthalmic testing, fundamentally reshaping how eye health is monitored and managed for a global patient base.

Olleyes, Inc. builds a portable, VR-based ophthalmic diagnostic platform (VisuALL) that runs visual field, acuity, color vision and related tests using AI, proprietary algorithms and eye‑tracking to enable clinic and at‑home testing for patients of all ages, including pediatric protocols and remote technician support[4][5].[1]

High‑Level Overview

• Concise summary: Olleyes is a New Jersey–based medtech company that commercializes the VisuALL virtual reality platform (VRP), a Class I/registered portable headset + cloud system for visual field and other ophthalmic testing that targets clinics, telehealth providers and at‑home monitoring scenarios[4][5].[1]
  - Product & customers: The VisuALL headset and software perform virtual visual field (VF) testing, visual acuity, color vision and pupilometry for ophthalmologists, optometrists and clinics, with special emphasis on accessibility (pediatric and mobility‑limited patients) and integration into practice workflows[4][2].[5]
  - Problem solved & impact: Olleyes reduces cost, increases portability, and expands access to standard automated perimetry—addressing barriers of bulky, expensive traditional perimeters and enabling testing outside conventional settings, which can improve screening, monitoring and patient flow in eye‑care practices[3][5].[1]
  - Growth momentum: The company has published peer‑reviewed studies and press announcing pediatric validation, added partnerships (eye‑tracking integration) and new service offerings (TechALL remote tech support), indicating product maturation and expanding service channels[1][3][5].[2]

Origin Story

• Founding & team: Olleyes was founded by neuro‑ophthalmologist Dr. Alberto Gonzalez‑Garcia, who serves as founder/CEO, with co‑founders including CTO Freddy Morgenstern and a multidisciplinary leadership team combining clinical, engineering and commercial backgrounds[4].
  - How the idea emerged: The team set out to create a lower‑cost, portable, patient‑friendly perimeter using VR, AI and proprietary algorithms to overcome access limitations of traditional perimetry and make high‑quality testing available in more settings[4][3].
  - Early traction / pivotal moments: Proof‑of‑concept studies showed VisuALL’s sensitivity comparable to standard Humphrey Field Analyzer testing and strong patient preference for the interactive VR testing; the company has filed patents and secured partnerships (e.g., for advanced eye‑tracking) and introduced offerings like TechALL remote ophthalmic technician support as it commercialized the product[3][1][5][2].

Core Differentiators

• Portable VR platform: A head‑mounted device that performs perimetry and other tests anywhere—clinic, bedside or home—versus traditional stationary perimeters[5][4].
  - Proprietary testing algorithms: “Dynamic Matrix” algorithm and AI workflows aim to improve efficiency and reduce fixation loss to near zero, speeding tests and improving reliability[2][5].
  - Pediatric and accessibility focus: Interactive, game‑like pediatric protocols and tests designed for patients with mobility or positioning challenges[3][5].
  - Integrated ecosystem: Device + cloud + app for data management and practice integration, with remote technician support (TechALL) to scale delivery and provide nationwide assistance[4][5].
  - Eye‑tracking & hardware partnerships: Integration of advanced eye‑tracking (partnerships announced) improves measurement accuracy and accounts for micro‑saccades and fixation variations[2][5].
  - Regulatory/clinical validation: FDA registration as a medical device (described in press coverage) and peer‑reviewed study results supporting pediatric performance[5][1][3].

Role in the Broader Tech Landscape

• Trend alignment: Olleyes rides the convergence of digital health, tele‑ophthalmology, VR/AR medical devices, AI‑driven diagnostics and remote monitoring—all accelerating adoption in the wake of telehealth expansion and demand for decentralized care[5][1].
  - Why timing matters: Aging populations and rising prevalence of diseases requiring visual field monitoring (glaucoma, diabetic retinopathy, AMD) increase demand for scalable, lower‑cost diagnostic options that support remote care and clinic efficiency[5][1].
  - Market forces in their favor: Shortages of specialized personnel, need for practice workflow optimization, and payer/system interest in earlier detection and remote follow‑up create opportunities for portable, validated testing tools[5][4].
  - Influence on ecosystem: By lowering equipment and logistical barriers, Olleyes can expand access to perimetry in underserved clinics, pediatrics, and home monitoring—potentially increasing case detection and enabling new tele‑ophthalmology service models[3][5].

Quick Take & Future Outlook

• What's next: Continued clinical validation, broader commercial adoption in practices and telehealth providers, expanded regulatory clearances, deeper integration with EMRs and practice management systems, and scaling of remote technician services (TechALL) are logical next steps indicated by recent product and service launches[1][5][4].
  - Trends that will shape them: Improvements in eye‑tracking hardware, AI diagnostic algorithms, reimbursement for remote diagnostics, and clinician acceptance of VR‑based testing will determine adoption speed and scope[2][5].
  - How influence may evolve: If Olleyes continues to demonstrate equivalence or superiority to traditional perimeters in sensitivity and usability, and secures reimbursement pathways, it could become a standard option for decentralized perimetry and routine monitoring—particularly for pediatrics and remote care[3][5].
  

Quick take: Olleyes is a clinically led medtech startup turning VR, AI and eye‑tracking into a portable perimetry ecosystem that addresses concrete access and workflow problems in eye care; its near‑term impact will depend on continued validation, integration, and reimbursement progress as it scales commercialization and remote support services[4][5][1].

If you want, I can:

• Summarize specific clinical study findings and citations for VisuALL’s performance.
  - Compile a timeline of press releases, partnerships and regulatory milestones.
  - Compare VisuALL feature‑by‑feature with a standard Humphrey Field Analyzer.